Nyrada – European Patent to be Granted for Cholesterol-Lowering Drug

The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9. The patent will provide protection for Nyrada’s PCSK9 inhibitor technology until 2038.
• Nyrada’s oral PCSK9 inhibitor creates the potential for a next generation alternative to expensive and inconvenient PCSK9 injectable drugs.
• Granting of the European patent will further strengthen the Company’s intellectual property portfolio, adding to the US patent already granted in July 2021.